Novartis (NVS) entered into an exclusive strategic license agreement with a clinical-stage biotechnology company, Arvinas, Inc. (ARVN) , for the worldwide development and commercialization of the latter’s pipeline candidate ARV-766.  Shares of ARVN were up on the news.The deal also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 program to Novartis.Per the terms of the deal, Novartis will be responsible for the global development and commercialization of ARV-766. NVS will als ...

裁员计划 - 诺华计划裁员680人，其中440人在瑞士，240人在美国[1],[2] - 这次裁员计划是独立于之前宣布的重组计划的，重组计划将裁员总全球员工数的8,000人[3] 研发部门情况 - 目前公司在研发部门约有12,500名员工，他们负责处理药品监管、分析和质量保证等支持功能，以及设计药品生产流程[4]

Novartis (NYSE:NVS) layoffs are in the news Wednesday after the healthcare company announced plans to cut jobs in the U.S. and Switzerland.Starting with its U.S. jobs, the company intends to reduce its headcount by 240 workers. Employees in its product development division will be the ones hit by these cuts.The same is true for the Novartis layoffs in Switzerland, which will affect 440 workers. Both the U.S. and Swiss layoffs are set to take place over the next two to three years.A spokesperson for Novartis ...

In the latest trading session, Novartis (NVS) closed at $95.79, marking a -1.14% move from the previous day. This change lagged the S&P 500's 1.11% gain on the day. Meanwhile, the Dow gained 0.8%, and the Nasdaq, a tech-heavy index, added 1.24%.The drugmaker's stock has dropped by 3.04% in the past month, falling short of the Medical sector's loss of 2.46% and the S&P 500's gain of 0.48%.Investors will be eagerly watching for the performance of Novartis in its upcoming earnings disclosure. It is anticipated ...

Pluvicto药物 - 诺华计划扩大其前列腺癌治疗药物Pluvicto的标签范围[1] - Pluvicto在患者在接受某些化疗药物之前使用时有助于提高生存率[2] - Pluvicto是诺华2023年销售增长最快的药物，销售额飙升262%，达到9.8亿美元[5] - 诺华计划在2024年下半年寻求扩大Pluvicto的使用批准[2] - Pluvicto在晚期试验中发现有助于提高晚期前列腺癌患者的总体生存率[4] - 诺华表示将在未来的医学会议上展示该研究的完整结果[6]

公司业绩 - 公司提高了每股收益预测至7瑞士法郎，估值达到101.5瑞士法郎每股[2] - 公司在2023年取得了积极的第三阶段试验结果，销售增长预期提高至2028年5%，2027年利润率超过40%[3] - 公司预计2024年销售额将增长4%至6%，核心运营利润预计为179亿美元[6] - 公司稍微提高了2024年每股收益至7.05美元，考虑到MorphoSys收购带来的利息支出增加[11] 公司收购 - 公司宣布以27亿美元现金收购MorphoSys AG，预计交易将于2024年上半年完成[7] - 公司看到了收购MorphoSys AG的战略合理性，预计pelabresib有望成为数十亿美元的畅销药[9] 估值和评级 - 公司目前的估值为每股102瑞士法郎，评级由中性调整为买入[14] 风险和展望 - 公司认为风险包括管线失败、激进的并购、关键药物上市的商业成功不佳、竞争加剧以及汇率波动等[15] - 总体而言，公司认为诺华正朝着提高销售额和利润的方向发展，股价经过最近的贬值后看起来便宜，管理层对中期增长和更高利润率的信心也增强，公司的资产负债表稳健，现在是一个长期买入的时机[16]

股价表现 - Novartis (NVS) 最近的股价为 $94.41，较前一个交易日收盘价下跌了 1.52%。[1] - 近一个月来，这家制药公司的股价下跌了 5.98%。[2] 行业比较 - Novartis 的股价下跌落后于医疗行业的下跌幅度 0.03%。[2] 财报预期 - 投资界将密切关注 Novartis 即将发布的财报表现。预计公司将报告每股收益为 $1.72，较去年同期增长 0.58%。[3] - 我们最新的共识估计预计公司的营收为 $114.1 亿美元，较去年同期下降了 11.9%。[4]

There are plenty of dividend stocks on the market. However, some raise their payouts irregularly, while others don't have businesses that look robust enough to support payout growth for a long time. Ideally, income-seeking investors want to avoid these situations. They prefer dividend-paying companies that can afford to raise their payouts regularly and aren't at risk of reducing or suspending their dividend programs.Let's look at one stock that can give income-seekers precisely what they want: Swiss pharma ...

股价表现 - Novartis (NVS) 最新收盘价为 $99.77，较前一交易日下跌了 -1.58% [1] - 近一个月来，这家制药公司的股价上涨了 0.84%，医疗行业上涨了 2.49%，而标普500指数上涨了 2.06% [2] 财务预测 - 投资者将密切关注 Novartis 即将公布的财报。预计每股收益为 $1.73，同比增长 1.17%，预计营收为 $11.43 亿美元，同比下降 11.75% [3] - 根据 Zacks Consensus Estimates，预计年度每股收益为 $7.18，营收为 $47.44 亿美元，分别较去年增长了 +4.06% 和下降了 -4.69% [4] 分析师预测 - 最近对 Novartis 的分析师预测变动也应引起投资者的注意，正面的预测修订可能预示着公司的良好前景 [5] - 研究表明，这些预测调整直接与即将到来的股价表现相关，投资者可以利用 Zacks Rank 模型来获取相关信息 [6] 行业比较 - Novartis 目前的前瞻市盈率为 14.13，低于行业的 14.31 [8] - NVS 目前的 PEG 比率为 1.57，考虑了公司的预期盈利增长轨迹，与 Large Cap Pharmaceuticals 行业的平均 PEG 比率 1.7 相比 [9] 行业排名 - Large Cap Pharmaceuticals 行业属于医疗行业，目前的 Zacks Industry Rank 为 172，位于所有 250+ 行业的后 32% [10] - 个别行业群体的实力由 Zacks Industry Rank 衡量，我们的研究显示，排名前 50% 的行业群体的表现是后 50% 的两倍 [11] 建议 - 请使用 Zacks.com 监控所有这些影响股价的指标，并在未来的交易中持续关注 [12]

In the latest trading session, Novartis (NVS) closed at $101.37, marking a +0.66% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.11%. Meanwhile, the Dow gained 0.12%, and the Nasdaq, a tech-heavy index, lost 0.41%.Prior to today's trading, shares of the drugmaker had lost 0.32% over the past month. This has lagged the Medical sector's gain of 3.03% and the S&P 500's gain of 2.7% in that time.The investment community will be closely monitoring the performance of No ...